Status:
COMPLETED
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Lead Sponsor:
Washington University School of Medicine
Conditions:
Lichen Planopilaris
Frontal Fibrosing Alopecia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Oral naltrexone was initially FDA approved to treat opioid use disorder and alcohol dependence at doses from 50-100mg/day. At lower doses of 1-5mg/day, naltrexone has been used off-label with success ...
Eligibility Criteria
Inclusion
- Adults age 18 or greater
- clinically or histologically confirmed diagnosis of lichen planopilaris or frontal fibrosing alopecia
Exclusion
- known allergy or hypersensitivity to naltrexone
- patients with concurrent use of opioids
- active depression, schizophrenia, and bipolar disorder
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT04409041
Start Date
September 1 2019
End Date
December 31 2020
Last Update
December 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University
St Louis, Missouri, United States, 63141